cTMTP1
cTMTP1 (Cyclic TMTP1) is the cyclic form of TMTP1 (HY-P11815). TMTP1 is a tumor-targeting peptide that selectively targets highly metastatic tumor cells. The cTMTP1-based [68Ga]Ga-DOTA-cTMTP1 probe is used for visualization of hepatocellular carcinoma. cTMTP1 can form a 68Ga-DOTA radiotracer that accumulates in highly metastatic cervical cancer cells and is used for microPET tumor visualization. cTMTP1 is applicable to research related to hepatocellular carcinoma and cervical cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Formule: C35H60N14O12S2
- Masse moléculaire:933.07
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform Radionuclide-Drug Conjugates (RDCs)
More
Activité biologique
|
RDC Peptide |
cTMTP1-based radiotracer 68Ga-DOTA-TMTP1 (~18.5 KBq/well; 15-120 min; 10 μg cold cyclic TMTP1 pre-incubated for 15 min followed by 60-120 min incubation) exhibits specific, high uptake and retention in highly metastatic HeLa cervical cancer cells compared to low metastatic C-33A cells and normal End1 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
[68Ga]Ga-DOTA-cTMTP1 (i.v.; single dose) maintains high tumor-to-liver ratios (ranging from 2.20 to 2.55) and enables sensitive detection of small HCC lesions in transgenic c-Myc liver tumor mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude (male, 5−6 weeks old, ~20 g, subcutaneous xenograft via right forelimb axillary injection of 2×106 SMMC-7721 cells)[1]
-
Dosage:5.2 MBq
-
Administration:i.v.; single dose
-
Result:Reached tumor uptake of 1.3 %ID/g at 15 min, 1.09 %ID/g at 30 min, and 0.74 %ID/g at 150 min postinjection.
Achieved tumor-to-liver ratios of 2.65 at 30 min, 2.37 at 60 min, 2.14 at 120 min, and 2.69 at 150 min postinjection.
Reached tumor-to-muscle ratio of 11.17 at 150 min postinjection.
Exhibited blood clearance of 1.11 %ID/g at 30 min, 0.48 %ID/g at 60 min, and 0.22 %ID/g at 120 min postinjection.
Reduced tumor uptake to 0.36 %ID/g at 30 min and 0.32 %ID/g at 60 min postinjection upon coinjection of excess linear TMTP1 (p < 0.01).
Chemical Information
-
Masse moléculaire 933.07
-
Formule C35H60N14O12S2
-
Synonyms
Cyclic TMTP1
-
Sequence
cyclo(Cys-Gly-Asn-Val-Val-Arg-Gln-Gly-Cys) (Disulfide bridge: Cys1-Cys9)
-
Sequence Shortening
cyclo(CGNVVRQGC) (Disulfide bridge: Cys1-Cys9)
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
[1]. Meng Z, et al. Development of a Cyclic TMTP1-Based PET Probe for Visualization of Hepatocellular Carcinoma. ACS medicinal chemistry letters. 2025 Apr 10;16(4):617-624. [Content Brief]
[2]. Chen X, et al. Ga-labeled TMTP1 radiotracer for PET imaging of cervical cancer. American journal of nuclear medicine and molecular imaging. 2024;14(2):110-121. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
cTMTP1 Related Classifications
HY-P11814 Related Classifications
Powered by Bioz
- cTMTP1
- Cyclic TMTP1
- cTMTP 1
- cTMTP-1
- Cyclic TMTP 1
- Cyclic TMTP-1
- Radionuclide-Drug Conjugates (RDCs)
- Drug Derivative
- cervical cancer
- HCC mouse models
- HeLa cervical cancer cells
- C-33A cells
- hepatocellular carcinoma
- End1 cells
- transgenic c-Myc liver tumor mice
- highly metastatic tumor cells
- XPNPEP2
- subcutaneous HCC xenograft mice
- Inhibitor
- inhibitor
- inhibit